The concept of peptide stacking becomes particularly relevant here, though any such approach should be guided by research and medical supervision
For instance, one such non-peptide-based GLP-1RA formulation, called Orforglipron (LY3502970), has been developed and is currently undergoing Phase III clinical trials (Wharton et al., 2025
FDA banned it in late 2023 "Category 2: Substance with Safety Concerns" Why the FDA banned it: Potential immune reactions (immunogenicity) Manufacturing impurities in compounded versions Complete lack of human safety data Risk of contamination Legal status: NOT FDA-approved Illegal to compound in pharmacies Banned by WADA for athletes Possession not illegal (it's not a DEA scheduled substance) Sold online as "research chemical" 2
[DOI] [PubMed] [Google Scholar] 801.Halim M.A., Degerblad M., Sundbom M., Karlbom U., Holst J.J., Webb D.L
GHK-Cu has also been reported to decrease the risk of infections